Shares of Novo Nordisk and Eli Lilly slipped in afternoon trade after the former announced a reduction in the list prices of its weight loss drugs, Ozempic and Wegovy.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Novo's 'Flashy' Ozempic, Wegovy Price Cuts Unlikely To Impact LLY Stock, Says BofA